Since these adverse HSPB8 effects in tamR cells prevent patients from benefiting from tamoxifen treatment, an alternative approach has been based on AZD8055, a mTOR kinase inhibitor, which downregulates HSPB8 expression in tamR BC cells. Here, HSPB8 is linked to breast cancer.